In the United States and globally, lung cancer deaths exceed the combined total of the next three most common cancers—colorectal, breast, and prostate—due to its high mortality rate and frequent late-stage diagnosis.

Here is the Federal Funding by Cancer Type:
National Institutes of Health (NIH) funding levels for the 2025/2026 period show a consistent lead for breast cancer, followed by prostate and colorectal, with lung cancer research receiving less despite its high mortality rate.   
 
Cancer Type   NIH Funding Amount      Funding Per Death 

Breast                     $1.58 Billion                        $69,800
Prostate                $663 Million                     $126,992
Colorectal            $494 Million                         $9,979

Lung (NSCLC)   $227 Million                          $1,754 

Lung (SCLC)      $62 Million                             $2,818

Despite lung cancer being the leader in death, is the loser in funding. I need your support. Spread this message. We need to increase funding for lung cancer. We need better screening for the never-smokers.

The U.S. Preventive Services Task Force (USPSTF) has no guidelines for the never-smokers, none. So it is found predominantly at stage 4. Without the right therapies stage 4 lung cancer patients median survival time is still only measured in a few months. We need to do better. We can do a lot better.

Spread this message.